Published on 22/12/2025
Improving Clinical Trial Site Selection with EHR Feasibility Analysis
Clinical trial success heavily depends on selecting the right sites—those capable of recruiting the appropriate patient populations efficiently. Traditional methods often rely on site-reported estimates or historical performance. However, integrating Electronic Health Records (EHRs) into feasibility assessments provides a data-driven way to optimize site selection for clinical trials and real-world evidence (RWE) studies.
This guide explains how pharma professionals and clinical trial experts can leverage EHR feasibility analysis for precision site selection, enhancing recruitment timelines, compliance, and trial success.
Why EHR-Based Site Feasibility is Critical:
Using EHRs for site selection offers distinct advantages:
- Real-time access to de-identified patient counts
- Granular data on eligibility criteria (e.g., age, comorbidities, lab values)
- Geographic insights into patient distribution
- Fewer protocol deviations due to better patient-site matching
- Data-driven predictions of enrollment timelines
By integrating EHR analysis, trial sponsors can confidently select high-performing sites, aligning with GMP quality expectations in study execution.
Step-by-Step Guide to EHR Feasibility Analysis:
- Define Eligibility Criteria:
Extract structured inclusion/exclusion parameters from the trial protocol—diagnosis codes, lab thresholds, medication history, and demographic filters.
- Map Criteria to EHR Variables:
Convert eligibility parameters into searchable EHR fields using standard terminologies like ICD-10, LOINC, or SNOMED CT. For example,
Work with sites using common data models (e.g., OMOP, PCORnet) or FHIR APIs to query de-identified patient counts who match trial criteria.
Include date-based logic like “diagnosed within past 6 months” or “medication use for >3 months” using EHR timestamps and structured entries.
Rank candidate sites based on number of eligible patients, historical enrollment metrics, and EHR data quality indicators.
Conduct virtual site visits to confirm feasibility analysis accuracy and assess operational capacity for protocol delivery.
Standardizing your feasibility workflow with structured SOPs is essential. Refer to Pharma SOP documentation for guidance on incorporating EHR-based metrics into selection checklists.
Tools Supporting EHR-Driven Site Feasibility:
Numerous platforms assist in EHR feasibility analysis:
- TriNetX: Global network of healthcare organizations providing queryable EHR data for trial planning.
- InSite: A platform developed by AstraZeneca and partners that leverages live EHR data across academic hospitals.
- ACT Network: NIH-funded tool allowing feasibility queries across U.S. research sites.
- i2b2: Open-source analytics platform enabling EHR feasibility queries in local data warehouses.
Many of these platforms align with StabilityStudies.in standards for data protection, anonymization, and ethical oversight.
Use Case: Oncology Trial Site Optimization
In a Phase III oncology study, a sponsor needed to identify sites that could enroll rare biomarker-positive patients. By querying hospital EHRs using genomic data, only three centers in the country matched eligibility at scale. Traditional feasibility would have failed to reveal this, leading to delays and low accrual.
EHR feasibility analysis enabled pre-selection of those sites, faster IRB submissions, and front-loaded recruitment—all within validated trial timelines.
Regulatory and Ethical Considerations:
- Patient Privacy: All EHR queries must be conducted on de-identified datasets, in accordance with HIPAA, GDPR, and institutional policies.
- IRB Oversight: Some queries may require IRB review or data access approvals before execution.
- Data Traceability: Ensure audit trails for all feasibility queries as per GCP and regulatory compliance.
As per CDSCO guidelines, EHR-based selection must not bias site access, and inclusion criteria should be uniformly applied across all potential centers.
Best Practices for Sponsors and CROs:
- Use a standardized feasibility request template across all sites
- Pre-map your inclusion/exclusion criteria to CDM-friendly terms
- Engage site informatics teams early in the feasibility process
- Validate query results with actual enrollment benchmarks post-trial
- Use feasibility metrics as key performance indicators (KPIs) in site contracts
Modern sponsors also adopt AI-driven tools that predict enrollment likelihood using EHR query results and historical site performance. These approaches reduce risk and increase ROI on trial investments.
Conclusion: Future of Site Selection is Data-Driven
EHR feasibility analysis is no longer optional—it’s a strategic enabler of trial efficiency, quality, and regulatory robustness. By embedding real-time EHR data into the feasibility process, pharma organizations can identify the right sites, reduce protocol amendments, and shorten startup timelines.
As clinical trials become more complex and competitive, data-driven site selection via EHRs is the key to sustainable success in real-world and interventional studies alike.